The Ras Effector RASSF2 Controls the PAR-4 Tumor Suppressor

REFERENCES

• Akino, K., M. Toyota, H. Suzuki, H. Mita, Y. Sasaki, M. Ohe-Toyota, J. P. Issa, Y. Hinoda, K. Imai, and T. Tokino. 2005. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129:156–169.
   PubMed Web of Science ®Google Scholar
• Boehrer, S., K. U. Chow, E. Puccetti, M. Ruthardt, S. Godzisard, A. Krapohl, B. Schneider, D. Hoelzer, P. S. Mitrou, V. M. Rangnekar, and E. Weidmann. 2001. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol. J. 2:103–107.
   PubMedGoogle Scholar
• Boehrer, S., D. Nowak, E. Puccetti, M. Ruthardt, N. Sattler, B. Trepohl, B. Schneider, D. Hoelzer, P. S. Mitrou, and K. U. Chow. 2006. Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis. Leuk. Res. 30:597–605.
   PubMedGoogle Scholar
• Calvisi, D. F., S. Ladu, A. Gorden, M. Farina, E. A. Conner, J. S. Lee, V. M. Factor, and S. S. Thorgeirsson. 2006. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130:1117–1128.
   PubMed Web of Science ®Google Scholar
• Chakraborty, M., S. G. Qiu, K. M. Vasudevan, and V. M. Rangnekar. 2001. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 61:7255–7263.
   PubMed Web of Science ®Google Scholar
• Cook, J., S. Krishnan, S. Ananth, S. F. Sells, Y. Shi, M. M. Walther, W. M. Linehan, V. P. Sukhatme, M. H. Weinstein, and V. M. Rangnekar. 1999. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18:1205–1208.
   PubMed Web of Science ®Google Scholar
• Cooper, W. N., R. E. Dickinson, A. Dallol, E. V. Grigorieva, T. V. Pavlova, L. B. Hesson, I. Bieche, M. Broggini, E. R. Maher, E. R. Zabarovsky, G. J. Clark, and F. Latif. 2008. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 27:1805–1811.
   PubMedGoogle Scholar
• Cooper, W. N., L. B. Hesson, D. Matallanas, A. Dallol, A. von Kriegsheim, R. Ward, W. Kolch, and F. Latif. 2009. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 28:2988–2998.
   PubMedGoogle Scholar
• Cottrell, S. E., J. Distler, N. S. Goodman, S. H. Mooney, A. Kluth, A. Olek, I. Schwope, R. Tetzner, H. Ziebarth, and K. Berlin. 2004. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. 32:e10.
   PubMed Web of Science ®Google Scholar
• Cox, A. D., and C. J. Der. 2003. The dark side of Ras: regulation of apoptosis. Oncogene 22:8999–9006.
   PubMed Web of Science ®Google Scholar
• Diaz-Meco, M. T., M. M. Municio, S. Frutos, P. Sanchez, J. Lozano, L. Sanz, and J. Moscat. 1996. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86:777–786.
   PubMed Web of Science ®Google Scholar
• Donninger, H., M. D. Vos, and G. J. Clark. 2007. The RASSF1A tumor suppressor. J. Cell Sci. 120:3163–3172.
   PubMed Web of Science ®Google Scholar
• Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11–22.
   PubMed Web of Science ®Google Scholar
• Eads, C. A., R. V. Lord, K. Wickramasinghe, T. I. Long, S. K. Kurumboor, L. Bernstein, J. H. Peters, S. R. DeMeester, T. R. DeMeester, K. A. Skinner, and P. W. Laird. 2001. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61:3410–3418.
   PubMed Web of Science ®Google Scholar
• El-Guendy, N., Y. Zhao, S. Gurumurthy, R. Burikhanov, and V. M. Rangnekar. 2003. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol. Cell. Biol. 23:5516–5525.
   PubMedGoogle Scholar
• Endoh, M., G. Tamura, T. Honda, N. Homma, M. Terashima, S. Nishizuka, and T. Motoyama. 2005. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br. J. Cancer 93:1395–1399.
   PubMedGoogle Scholar
• Fenton, S. L., A. Dallol, A. Agathanggelou, L. Hesson, J. Ahmed-Choudhury, S. Baksh, C. Sardet, R. Dammann, J. D. Minna, J. Downward, E. R. Maher, and F. Latif. 2004. Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res. 64:102–107.
   PubMedGoogle Scholar
• Fiordalisi, J. J., R. L. Johnson II, A. S. Ulku, C. J. Der, and A. D. Cox. 2001. Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. Methods Enzymol. 332:3–36.
   PubMedGoogle Scholar
• Garcia-Cao, I., A. Duran, M. Collado, M. J. Carrascosa, J. Martin-Caballero, J. M. Flores, M. T. Diaz-Meco, J. Moscat, and M. Serrano. 2005. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep. 6:577–583.
   PubMed Web of Science ®Google Scholar
• Garcia-Cao, I., M. J. Lafuente, L. M. Criado, M. T. Diaz-Meco, M. Serrano, and J. Moscat. 2003. Genetic inactivation of Par4 results in hyperactivation of NF-κB and impairment of JNK and p38. EMBO Rep. 4:307–312.
   PubMedGoogle Scholar
• Goswami, A., R. Burikhanov, A. de Thonel, N. Fujita, M. Goswami, Y. Zhao, J. E. Eriksson, T. Tsuruo, and V. M. Rangnekar. 2005. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol. Cell 20:33–44.
   PubMed Web of Science ®Google Scholar
• Guo, C., S. Tommasi, L. Liu, J. K. Yee, R. Dammann, and G. P. Pfeifer. 2007. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr. Biol. 17:700–705.
   PubMed Web of Science ®Google Scholar
• Gurumurthy, S., A. Goswami, K. M. Vasudevan, and V. M. Rangnekar. 2005. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol. Cell. Biol. 25:1146–1161.
   PubMed Web of Science ®Google Scholar
• Hesson, L. B., R. Wilson, D. Morton, C. Adams, M. Walker, E. R. Maher, and F. Latif. 2005. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 24:3987–3994.
   PubMedGoogle Scholar
• Imai, T., M. Toyota, H. Suzuki, K. Akino, K. Ogi, Y. Sogabe, L. Kashima, R. Maruyama, M. Nojima, H. Mita, Y. Sasaki, F. Itoh, K. Imai, Y. Shinomura, H. Hiratsuka, and T. Tokino. 2008. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci. 99:958–966.
   PubMedGoogle Scholar
• Joshi, J., P. J. Fernandez-Marcos, A. Galvez, R. Amanchy, J. F. Linares, A. Duran, P. Pathrose, M. Leitges, M. Canamero, M. Collado, C. Salas, M. Serrano, J. Moscat, and M. T. Diaz-Meco. 2008. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J. 27:2181–2193.
   PubMedGoogle Scholar
• Kaira, K., N. Sunaga, Y. Tomizawa, N. Yanagitani, T. Ishizuka, R. Saito, T. Nakajima, and M. Mori. 2007. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int. J. Oncol. 31:169–173.
   PubMed Web of Science ®Google Scholar
• Khokhlatchev, A., S. Rabizadeh, R. Xavier, M. Nedwidek, T. Chen, X. F. Zhang, B. Seed, and J. Avruch. 2002. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12:253–265.
   PubMed Web of Science ®Google Scholar
• Kumari, G., P. K. Singhal, M. R. Rao, and S. Mahalingam. 2007. Nuclear transport of Ras-associated tumor suppressor proteins: different transport receptor binding specificities for arginine-rich nuclear targeting signals. J. Mol. Biol. 367:1294–1311.
   PubMedGoogle Scholar
• Liu, J. W., J. K. Nagpal, C. Jeronimo, J. E. Lee, R. Henrique, M. S. Kim, K. L. Ostrow, K. Yamashita, V. van Criekinge, G. Wu, C. S. Moon, B. Trink, and D. Sidransky. 2008. Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate 68:418–426.
   PubMedGoogle Scholar
• Malumbres, M., and M. Barbacid. 2003. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3:459–465.
   PubMed Web of Science ®Google Scholar
• Maruyama, R., K. Akino, M. Toyota, H. Suzuki, T. Imai, M. Ohe-Toyota, E. Yamamoto, M. Nojima, T. Fujikane, Y. Sasaki, T. Yamashita, Y. Watanabe, H. Hiratsuka, K. Hirata, F. Itoh, K. Imai, Y. Shinomura, and T. Tokino. 2008. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 29:1312–1318.
   PubMedGoogle Scholar
• Model, F., N. Osborn, D. Ahlquist, R. Gruetzmann, B. Molnar, F. Sipos, O. Galamb, C. Pilarsky, H. D. Saeger, Z. Tulassay, K. Hale, S. Mooney, J. Lograsso, P. Adorjan, R. Lesche, A. Dessauer, J. Kleiber, B. Porstmann, A. Sledziewski, and C. Lofton-Day. 2007. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol. Cancer Res. 5:153–163.
   PubMed Web of Science ®Google Scholar
• Moreno-Bueno, G., P. J. Fernandez-Marcos, M. Collado, M. J. Tendero, S. M. Rodriguez-Pinilla, I. Garcia-Cao, D. Hardisson, M. T. Diaz-Meco, J. Moscat, M. Serrano, and J. Palacios. 2007. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res. 67:1927–1934.
   PubMed Web of Science ®Google Scholar
• Nalca, A., S. G. Qiu, N. El-Guendy, S. Krishnan, and V. M. Rangnekar. 1999. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J. Biol. Chem. 274:29976–29983.
   PubMed Web of Science ®Google Scholar
• Park, H. W., H. C. Kang, I. J. Kim, S. G. Jang, K. Kim, H. J. Yoon, S. Y. Jeong, and J. G. Park. 2007. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int. J. Cancer 120:7–12.
   PubMedGoogle Scholar
• Pearson, H. B., T. J. Phesse, and A. R. Clarke. 2009. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 69:94–101.
   PubMed Web of Science ®Google Scholar
• Pruitt, K., A. S. Ulku, K. Frantz, R. J. Rojas, V. M. Muniz-Medina, V. M. Rangnekar, C. J. Der, and J. M. Shields. 2005. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J. Biol. Chem. 280:23363–23370.
   PubMedGoogle Scholar
• Qiu, G., M. Ahmed, S. F. Sells, M. Mohiuddin, M. H. Weinstein, and V. M. Rangnekar. 1999. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18:623–631.
   PubMed Web of Science ®Google Scholar
• Sells, S. F., S. S. Han, S. Muthukkumar, N. Maddiwar, R. Johnstone, E. Boghaert, D. Gillis, G. Liu, P. Nair, S. Monnig, P. Collini, M. P. Mattson, V. P. Sukhatme, S. G. Zimmer, D. P. Wood, Jr., J. W. McRoberts, Y. Shi, and V. M. Rangnekar. 1997. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol. Cell. Biol. 17:3823–3832.
   PubMed Web of Science ®Google Scholar
• Sells, S. F., D. P. Wood, Jr., S. S. Joshi-Barve, S. Muthukumar, R. J. Jacob, S. A. Crist, S. Humphreys, and V. M. Rangnekar. 1994. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ. 5:457–466.
   PubMedGoogle Scholar
• Shareef, M. M., N. Cui, R. Burikhanov, S. Gupta, S. Satishkumar, S. Shajahan, M. Mohiuddin, V. M. Rangnekar, and M. M. Ahmed. 2007. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res. 67:11811–11820.
   PubMed Web of Science ®Google Scholar
• Tommasi, S., R. Dammann, Z. Zhang, Y. Wang, L. Liu, W. M. Tsark, S. P. Wilczynski, J. Li, M. You, and G. P. Pfeifer. 2005. Tumor susceptibility of Rassf1a knockout mice. Cancer Res. 65:92–98.
   PubMed Web of Science ®Google Scholar
• van der Weyden, L., and D. J. Adams. 2007. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim. Biophys. Acta 1776:58–85.
   PubMed Web of Science ®Google Scholar
• Vos, M. D., A. Dallol, K. Eckfeld, N. P. Allen, H. Donninger, L. B. Hesson, D. Calvisi, F. Latif, and G. J. Clark. 2006. The RASSF1A tumor suppressor activates Bax via MOAP-1. J. Biol. Chem. 281:4557–4563.
   PubMed Web of Science ®Google Scholar
• Vos, M. D., C. A. Ellis, A. Bell, M. J. Birrer, and G. J. Clark. 2000. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 275:35669–35672.
   PubMed Web of Science ®Google Scholar
• Vos, M. D., C. A. Ellis, C. Elam, A. S. Ulku, B. J. Taylor, and G. J. Clark. 2003. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol. Chem. 278:28045–28051.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., D. Sun, N. Van do, A. Tang, L. Hu, and G. Huang. 2007. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int. J. Cancer. 120:32–38.
   PubMedGoogle Scholar
• Zhao, Y., R. Burikhanov, S. Qiu, S. M. Lele, C. D. Jennings, S. Bondada, B. Spear, and V. M. Rangnekar. 2007. Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res. 67:9276–9285.
   PubMed Web of Science ®Google Scholar